缩宫素、缩宫素/麦角新碱与卡贝缩宫素预防阴道分娩后原发性产后出血的随机对照试验方案(IMox研究)
IMox研究是一项前瞻性、多中心、双盲、随机试验,直接比较缩宫素、缩宫素/麦角新碱和卡贝缩宫素肌内注射预防阴道分娩后产后出血的效果。主要结局为额外使用宫缩剂,计划样本5712例(每组1904例),同时评估可接受性和成本效果。
要点
- 首个直接比较三种宫缩剂预防阴道分娩后产后出血的随机试验。
- 主要结局为额外使用宫缩剂,计划样本5712例。
- 同时评估药物可接受性和成本效果。
核心结论
- IMox研究旨在确定阴道分娩后原发性产后出血预防中最有效、可接受且成本效果好的药物。
研究设计与样本
- 前瞻性、多中心、双盲、随机对照试验,在英格兰六家医院招募计划阴道分娩的孕妇。
- 从妊娠20周至进入活跃产程期间邀请参与并获取知情同意。
- 计划样本5712例(每组1904例)提供主要结局数据,以稳健确定三种药物间的疗效差异。
- 数据分析基于改良意向性治疗,并额外按方案分析。
- 数据收集于2015年2月开始,2018年8月完成。
关键数值与推荐
- 主要有效性结局为额外使用宫缩剂。
- 次要有效性结局反映产后即刻母婴发病率和死亡率。
- 通过问卷和主观报告评估产妇可接受性。
- 在产前及产后第1天和第14天收集产妇生活质量效用值以进行成本效果评估。
局限性
- 研究仅使用短期结局,无法提供长期 maternal 心理健康和再次受孕时间等重要结局的证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Postpartum haemorrhage remains a major cause of maternal mortality and morbidity worldwide. Active management of the third stage of labour reduces the risk of postpartum haemorrhage. Oxytocin and oxytocin/ergometrine are commonly used in the UK, with oxytocin/ergometrine being more effective at preventing moderate, but not severe, blood loss. Many guidelines specifically recommend using oxytocin for all vaginal births, as it is associated with fewer adverse events. However, a survey conducted by the Southmead Hospital Maternity Research Team revealed that 71.4% of UK obstetric units still routinely use oxytocin/ergometrine. Carbetocin is a newer medication that may be as effective but has fewer side effects. No studies have directly compared all three medications. METHODS: The IMox study aims to determine the most effective, acceptable and cost-effective drug for primary prevention of postpartum haemorrhage following vaginal birth. The IMox study is a prospective, multi-centre, double-blind, randomised trial directly comparing oxytocin, oxytocin/ergometrine and carbetocin given intramuscularly for the prevention of postpartum haemorrhage in the third stage of labour. The primary effectiveness outcome is the use of an additional uterotonic drug. Secondary effectiveness outcomes reflect maternal morbidity and mortality within the immediate postpartum period. Participant questionnaires and subjective reporting of side effects will be used to evaluate maternal acceptability. Maternal quality of life utilities will be collected antenatally, and on days 1 and 14 after birth to enable a cost-effectiveness assessment of each studied drug. Participants will be pregnant women planning a vaginal birth in six hospitals in England. Participants will be approached and invited to provide consent to participate from 20 weeks gestation until in established labour. A complete sample of 5712 participants (1904 per arm) providing data for the primary outcome will allow for a robust determination of efficacy between all three study drugs. Data will be collected until participants are discharged from the hospital and on postnatal days 1 and 14 regardless of location. All analyses will be on a modified intention-to-treat basis, and additionally repeated on a per protocol basis. Data collection commenced in Feburary 2015 and was completed in August 2018. DISCUSSION: This study is the first to directly compare oxytocin, oxytocin/ergometrine and carbetocin in the same population for the prevention of postpartum haemorrhage following vaginal birth. Furthermore, this study will be the first to directly compute health economic outcomes from such a three-way comparison. This study is limited to using short-term outcomes, and so will not provide evidence for important outcomes such as long-term maternal psychological well-being and time to next conception. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02216383 . Registered on 18 August 2014. EudraCT, 2014-001948-37. Registered on 23 September 2014. ISRCTN, ISRCTN10232550. Retrospectively registered on 6 March 2018).
引用
- van der Nelson H, O'Brien S, Lenguerrand E, et al. Intramuscular oxytocin versus oxytocin/ergometrine versus carbetocin for prevention of primary postpartum haemorrhage after vaginal birth: study protocol for a randomised controlled trial (the IMox study). Trials. 2019. PMID: 30606246. doi:10.1186/s13063-018-3109-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。